A bit worried about sales to low income countries and possible impact on revenues and earnings in Q3 2021. As $(BNTX)$ revenues are 50% of gross profit recorded by pfizer on Comirnaty sales (excluding Germany and Turkey), a question mark remains on how this gross profit was impacted by lower prices in Q3 and this despite increasing sales (a reduction of 50% on sale price would translate into a reduction in gross profit of roughly 80% on profits assuming a gross margin of 70%). Can anybody advice?